# Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

> **NCT03385239** · PHASE2 · COMPLETED · sponsor: **Akcea Therapeutics** · enrollment: 114 (actual)

## Conditions studied

- Hypertriglyceridemia
- Cardiovascular Diseases

## Interventions

- **DRUG:** ISIS 678354
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03385239
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2019-11-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2023-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03385239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03385239, "Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03385239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*